Zygogen Uses Zebrafish to Find Angiogenesis Inhibitor; Findings Translate to Human CBAs | GenomeWeb
BOSTON — A prospective study by researchers at Zygogen have found what they believe to be the first anti-angiogenic compound initially identified in live zebrafish whose activity they were able to translate to human cell-based assays.
Eric Sandberg, a Zygogen scientist, told CBA News this week that up until his firm’s research, all studies looking at the effect of anti-angiogenic compounds in zebrafish were done retrospectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.